Entry

D12241                      Drug

Name

Regdanvimab (INN);
Regkirona (TN)

Sequence

(Heavy chain)
QITLKESGPT LVKPTQTLTL TCSFSGFSLS TSGVGVGWIR QPPGKALEWL ALIDWDDNKY
HTTSLKTRLT ISKDTSKNQV VLTMTNMDPV DTATYYCARI PGFLRYRNRY YYYGMDVWGQ
GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT
FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC
PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT
KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
ELVLTQPPSV SAAPGQKVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY DNNKRPSGIP
DRFSGSKSGT SATLGITGLQ TGDEADYYCG TWDSSLSAGV FGGGTELTVL GQPKAAPSVT
LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADGSPVK AGVETTKPSK QSNNKYAASS
YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS
(Disulfide bridge: H22-H97, H155-H211, H231-L215, H237-H'237, H240-H'240, H272-H332, H378-H436, H'22-H'97, H'155-H'211, H'231-L'215, H'272-H'332, H'378-H'436, L22-L89, L138-L197, L'22-L'89, L'138-L'197)

Type

Peptide

Class

Antiviral
DG03174 Anti-SARS-CoV-2 agent

Efficacy

Antiviral

Comment

Monoclonal antibody
Treatment of adults with coronavirus disease 2019 (COVID-19)

Target

SARS-CoV-2 spike glycoprotein [KO:K24152]

Pathway

ko03230

Viral genome structure

ko05171

Coronavirus disease - COVID-19

Brite

Drug groups [BR:br08330]
Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12241  Regdanvimab
Antimicrobials [BR:br08307]
Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12241  Regdanvimab (INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D12241
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D12241

Other DBs

CAS:	2444308-95-4